Sirtex is a global life-sciences company that markets SIR-Spheres® Y-90 resin microspheres, a targeted radiation therapy for patients with inoperable primary or secondary (metastatic) liver tumours. Sirtex has supplied over 100,000 doses of SIR-Spheres Y-90 resin microspheres to 1400 centres in over 50 countries worldwide.
Our significant investments in people, research, product development, marketing, clinical studies and other sales growth initiatives has created a foundation for a global business that will continue to create value over the coming years.
The vision of Sirtex is that cancer will no longer be a terminal disease …but a disease that patients can successfully live with.
The global Sirtex team over the past few years has grown significantly and we now have over 266 employees located in 20 countries.
The Global Head Office of Sirtex is located in Boston, USA, the European, Middle East, African (EMEA) Regional Headquarters is located in Bonn, Germany and the Asia Pacific Regional Headquarters is located in Sydney Australia.